Why Now Is The Perfect Time To Buy GlaxoSmithKline plc

Buying a slice of GlaxoSmithKline plc (LON: GSK) could be a great move. Here’s why.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Life as a shareholder of GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) has not been particularly rewarding of late. For example, shares in the pharmaceutical major have risen by just 12% in the last five years, which is behind even a disappointing FTSE 100 rise of 18% in the same time period. However, now could be the start of a much more prosperous period for investors in GlaxoSmithKline, and this could be the right time to buy.

Declining Sentiment

Slowing sales growth and bribery allegations have been two of the major reasons for the decline in investor sentiment in recent years. Certainly, the problems that GlaxoSmithKline has faced in regard to generic competition are not unique, with a number of other global pharmaceutical stocks also struggling to replace key, blockbuster drugs that are moving off-patent and coming under threat from generic competition.

And, in GlaxoSmithKline’s case, it has felt the effects of this to a lesser extent than many of its peers, with its top line holding up reasonably well during the last five years relative to peers such as AstraZeneca. In fact, while GlaxoSmithKline’s sales have fallen by 13% during the period, AstraZeneca’s are down by 26%, and yet AstraZeneca’s share price is up a whopping 55% in the last five years.

Clearly, the bribery allegations and subsequent fine of around £300 million in China have weighed heavily on investors’ minds. This dominated GlaxoSmithKline’s news flow last year and has been a big contributor to its disappointing share price performance.

Looking Ahead

However, GlaxoSmithKline has bright prospects following a challenging period. Its drug pipeline remains a major draw for investors and its ViiV Healthcare division, for instance, has the potential to deliver multiple blockbuster drugs for HIV. In fact, it could be spun off from GlaxoSmithKline, such is its long term potential.

And, looking ahead to next year, the company is forecast to grow its top line by 3.1% which, although not spectacular, shows that it is set to move in the right direction after years of declining sales. Of course, generic competition will not go away, but GlaxoSmithKline seems to have the arsenal (via its pipeline) to overcome patent losses over the medium to long term.

Furthermore, GlaxoSmithKline continues to be relatively financially sound. For example, while its balance sheet does carry considerable debt, its vast profitability ensures that interest payments remain very well-covered at over 9 times and, as a result, it appears to have the financial firepower to continue to invest heavily in its pipeline and even conduct significant M&A activity.


Having risen by just 12% in five years, shares in GlaxoSmithKline trade on a relatively appealing valuation. While earnings growth is forecast to be lacking this year, the company’s bottom line could rise at a brisk pace over the medium term, with 2016 set to see it grow by around 6%. As such, a price to earnings (P/E) ratio of 15.3 seems to be well worth paying for a company that has such a bright long term future. As a result, now could be a great time to buy GlaxoSmithKline.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of GlaxoSmithKline and AstraZeneca. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Mature Caucasian woman sat at a table with coffee and laptop while making notes on paper
Dividend Shares

How I’d try to ironclad my second income before interest rates fall

Jon Smith explains a couple of tactics he's looking to implement in his dividend portfolio to try and protect his…

Read more »

Investing Articles

The FTSE 100 still looks cheap to me. But don’t just take my word for it!

The FTSE 100 (INDEXFTSE:UKX) has increased 7.5% since the start of 2024. But I think there’s evidence to suggest that…

Read more »

Investing Articles

What should the Vodafone share price be? Here are 3 possible answers

Our writer uses a number of popular financial measures to come up with an estimate of a fair value for…

Read more »

Investing Articles

Here’s how much I’d have if I’d bought 1,000 shares in this FTSE 100 defence stock 5 years ago

I could have made a pretty penny investing in this leading FTSE 100 defence stock. Now I’m looking at a…

Read more »

Investing Articles

1 potential millionaire-maker UK stock I’d like to buy for the long haul

For long-term investors, here’s 1 UK stock to consider buying right now with the potential to help power a growth…

Read more »

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
Investing Articles

These cheap UK shares look way too good to ignore right now

With the UK stock market reaching new highs recently, this Fool plans to grab these two remaining cheap shares before…

Read more »

Young Woman Drives Car With Dog in Back Seat
Investing Articles

This unloved UK stock could rise 120%, according to a City broker

Some City analysts reckon a once-popular UK stock can recover from its massive recent decline and go on to more…

Read more »

Investing Articles

These FTSE dividend shares all offer 6%+ yields!

Paul Summers highlights three FTSE dividend shares that offer big yields. But is the passive income stream sufficient to offset…

Read more »